Skip to content Skip to footer
Subscribe Now
Spotlight Interview_Nazeen Rahman
EVENTS

Reuters Pharma 2025: Pre-Conference Talks Featuring Nazneen Rahman

In this thought-provoking Podcast, Nazneen Rahman Founder and CEO of YewMaker shares a glimpse of her upcoming presentation at the Reuters Pharma 2025 event on “Accelerate Access to Medicine: Unite for Global Health Equity” Nazneen talks about fostering science-based scalable solutions to promote sustainability in the biopharma industry. PharmaShots was delighted to learn about YewMaker’s…
April 8, 2025

Read more

Spotlight Interview_Ana Cerdeira
EVENTS

Reuters Pharma 2025: Pre-Conference Talks Featuring Ana Cerdeira

Ana Cerdeira, Vice President, Global Head Commercial, Development Assets, Innovative Medicines Group, Grunenthal in a stimulating conversation with PharmaShots’ Managing Director Himanshu Sehgal. Ana will be joining the upcoming Reuters Events Pharma 2025 as a panelist for the topic “Value unleashed: Elevate patient, HCP, and payer engagement with holistic storytelling tools and RWE”. In this…
April 8, 2025

Read more

Spotlight Interview_Philippe Barillon
EVENTS

Reuters Pharma 2025: Pre-Conference Talks Featuring Philippe Barillon

Philippe Barillon joins PharmaShots Managing Editor Himanshu Sehgal for an enlightening dialogue exchange in a Pre-Conference Talk. Philippe will be joining the upcoming Reuters Events Pharma 2025 as a panelist for the topic “Bridging gaps: Leverage data, tech and RWE for enhanced healthcare access and market growth”. Philippe highlights the potential applications of RWEs using…
April 7, 2025

Read more

Viewpoints_Raphaël Ortiz
VIEWPOINTS

Enhancing Diagnostic Capabilities in Prostate Cancer: Raphaël Ortiz from Telix Pharmaceuticals in a Riveting Conversation with PharmaShots

Shots:  Telix Pharmaceuticals’ Illuccix is approved in the UK for detecting and localizing prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, using PET imaging.  Amidst a shortage of PET imaging agents in the UK and mainland Europe, Telix Pharmaceuticals has secured a significant advantage through an exclusive distribution partnership with Xiel Limited  Raphaël…
April 7, 2025

Read more

Spotlight Interview_Konrad Dobschuetz
EVENTS

Reuters Pharma 2025: Pre-Conference Talks Featuring Konrad Dobschuetz

Konrad Dobschuetz, Founder Director at Leap Advisory & Intelligence will be conducting a workshop at the upcoming Reuters Events Pharma 2025 on the topic “Patient Centricity”. In the exclusive discussion with PharmaShots, Konrad addresses the need for biopharma companies to achieve a patient mindset to deliver patient-centric care and enhance the patient experience. Konrad believes…
April 4, 2025

Read more

Viewpoints_Roger Levy
VIEWPOINTS

Evaluating SDoH in Lupus Nephritis: Roger Levy from GSK in a Stimulating Conversation with PharmaShots

Shots:  GSK presented data at the American College of Rheumatology from a multi-center cohort study highlighting the achievement of complete renal response in patients with active lupus nephritis  The study evaluated the attainment of modified complete renal response (mCRR) in patients with systemic lupus erythematosus (SLE) and active lupus nephritis (LN), comparing characteristics between mCRR…
April 2, 2025

Read more

Spotlight Interview_Rahul Mittal
EVENTS

Reuters Pharma USA 2025: Post-Conference Talks featuring Rahul Mittal

Brimming with insightful panel discussions, presentations on disruptive technologies, and illuminating real-world evidence shaping the healthcare landscape now and then, the two-day Reuters event celebrated pharmaceutical innovation and fresh perspectives pouring into the interactive sessions. In the panel discussion at Reuters Pharma USA 2025, Rahul Mittal outlined ways to enhance patient centricity and engagement. Rahul…
March 31, 2025

Read more

Viewpoints_Anabela Cardoso_Mark Genovese
VIEWPOINTS

Lilly at ACG 2024: Anabela Cardoso and Mark Genovese in Conversation with PharmaShots

Shots:  Lilly presented results from two long-term studies evaluating sustained efficacy in patients treated with mirikizumab for both moderately to severely active Ulcerative Colitis and Crohn’s Disease at ACG 2024  At three years, more than 80 percent of patients with moderately to severely active ulcerative colitis who were on remission sustained long-term remission and relief  …
March 24, 2025

Read more

Load more